John P. Perentesis

Genomic imprinting of H19 and insulin‐like growth factor‐2 in pediatric germ cell tumors

J. Perentesis, J. Ross, S. Davies, 1999, Cancer.

A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

Rachel A. Kudgus, J. Perentesis, J. Reid, 2017, Pediatric blood & cancer.